Angiopoietin as a Novel Prognostic Marker in Kidney Disease.

IF 2.2 3区医学 Q3 HEMATOLOGY Blood Purification Pub Date : 2024-01-01 Epub Date: 2024-01-23 DOI:10.1159/000536439

Abdullah B Yildiz, Sidar Copur, Cem Tanriover, Furkan Yavuz, Sezan Vehbi, Abduzhappar Gaipov, Lorenza Magagnoli, Paola Ciceri, Mario Cozzolino, Mehmet Kanbay

{"title":"Angiopoietin as a Novel Prognostic Marker in Kidney Disease.","authors":"Abdullah B Yildiz, Sidar Copur, Cem Tanriover, Furkan Yavuz, Sezan Vehbi, Abduzhappar Gaipov, Lorenza Magagnoli, Paola Ciceri, Mario Cozzolino, Mehmet Kanbay","doi":"10.1159/000536439","DOIUrl":null,"url":null,"abstract":"Introduction: Renal injury is among the leading causes of morbidity and mortality; however, there are no reliable indicators for determining the likelihood of developing chronic kidney disease (CKD), CKD progression, or AKI events. Vascular growth factors called angiopoietins have a role in endothelial function, vascular remodeling, tissue stabilization, and inflammation and have been implicated as prognostic and predictive markers in AKI.Methods: Although the exact mechanism of the relationship between kidney injury and angiopoietins is unknown, this review demonstrates that AKI patients have higher angiopoietin-2 levels and that higher angiopoietin-1 to angiopoietin-2 ratio may potentially be linked with a reduced risk of the CKD progression.Results: This review therefore emphasizes the importance of angiopoietin-2 and proposes that it could be an important predictor of AKI in clinical settings.Conclusion: There is a need for further large-scale randomized clinical trials in order to have a better understanding of the significance of angiopoietin-2 and for the determination of its potential clinical implications.","PeriodicalId":8953,"journal":{"name":"Blood Purification","volume":" ","pages":"425-435"},"PeriodicalIF":2.2000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Blood Purification","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000536439","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/23 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Renal injury is among the leading causes of morbidity and mortality; however, there are no reliable indicators for determining the likelihood of developing chronic kidney disease (CKD), CKD progression, or AKI events. Vascular growth factors called angiopoietins have a role in endothelial function, vascular remodeling, tissue stabilization, and inflammation and have been implicated as prognostic and predictive markers in AKI.

Methods: Although the exact mechanism of the relationship between kidney injury and angiopoietins is unknown, this review demonstrates that AKI patients have higher angiopoietin-2 levels and that higher angiopoietin-1 to angiopoietin-2 ratio may potentially be linked with a reduced risk of the CKD progression.

Results: This review therefore emphasizes the importance of angiopoietin-2 and proposes that it could be an important predictor of AKI in clinical settings.

Conclusion: There is a need for further large-scale randomized clinical trials in order to have a better understanding of the significance of angiopoietin-2 and for the determination of its potential clinical implications.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

血管生成素是肾脏疾病的新型预后标志物

肾损伤是发病率和死亡率的主要原因之一，但目前还没有可靠的指标来确定患慢性肾功能衰竭、慢性肾功能衰竭进展或急性肾损伤事件的可能性。被称为血管生成素的血管生长因子在内皮功能、血管重塑、组织稳定和炎症中发挥作用，被认为是 AKI 的预后和预测标志物。虽然肾损伤与血管生成素之间关系的确切机制尚不清楚，但本综述表明，AKI 患者的血管生成素-2 水平较高，而血管生成素-1 与血管生成素-2 的比率较高可能与慢性肾病进展的风险降低有关。因此，本综述强调了血管生成素-2 的重要性，并提出它可能是临床环境中预测 AKI 的重要指标。有必要进一步开展大规模随机临床试验，以便更好地了解血管生成素-2 的重要性，并确定其潜在的临床意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Blood Purification 医学-泌尿学与肾脏学

CiteScore

5.80

自引率

3.30%

发文量

审稿时长

6-12 weeks

期刊介绍： Practical information on hemodialysis, hemofiltration, peritoneal dialysis and apheresis is featured in this journal. Recognizing the critical importance of equipment and procedures, particular emphasis has been placed on reports, drawn from a wide range of fields, describing technical advances and improvements in methodology. Papers reflect the search for cost-effective solutions which increase not only patient survival but also patient comfort and disease improvement through prevention or correction of undesirable effects. Advances in vascular access and blood anticoagulation, problems associated with exposure of blood to foreign surfaces and acute-care nephrology, including continuous therapies, also receive attention. Nephrologists, internists, intensivists and hospital staff involved in dialysis, apheresis and immunoadsorption for acute and chronic solid organ failure will find this journal useful and informative. ''Blood Purification'' also serves as a platform for multidisciplinary experiences involving nephrologists, cardiologists and critical care physicians in order to expand the level of interaction between different disciplines and specialities.